These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 32744106)
1. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies. Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106 [TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
3. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF; Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359 [TBL] [Abstract][Full Text] [Related]
4. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K Front Immunol; 2021; 12():646874. PubMed ID: 33927719 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578 [TBL] [Abstract][Full Text] [Related]
6. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655 [TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis. Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y Front Immunol; 2023; 14():1060308. PubMed ID: 36949944 [TBL] [Abstract][Full Text] [Related]
10. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828 [TBL] [Abstract][Full Text] [Related]
11. Tumor Mutational Burden and Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858 [TBL] [Abstract][Full Text] [Related]
12. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535 [TBL] [Abstract][Full Text] [Related]
13. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185 [TBL] [Abstract][Full Text] [Related]
14. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895 [TBL] [Abstract][Full Text] [Related]
15. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203 [TBL] [Abstract][Full Text] [Related]
16. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
17. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Qian X; Chen H; Tao Y Front Immunol; 2023; 14():1146898. PubMed ID: 37063822 [TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]